A Phase 1b Clinical Study of NXP900 in Combination With Osimertinib in Subjects With Advanced, EGFRMut+ Non-Small Cell Lung Cancer
This study is testing a new medication called NXP900 along with an existing cancer drug called osimertinib. It aims to help adults with a common type of advanced lung cancer who have already tried osimertinib and need new treatment options.
You might be able to join if you are 18 or older, can handle normal daily activities, and have advanced lung cancer with a specific EGFR gene change that has been previously treated with osimertinib.
Participants will take the study medication NXP900 combined with osimertinib and will have regular check-ups with the medical team to monitor their health and how they respond to the treatment.
This study is currently recruiting patients at medical locations in Maryland, Massachusetts, and Oregon in the United States.
- 1Tests a combination of NXP900 and osimertinib for advanced lung cancer
- 2For adults who have previously been treated with osimertinib
- 3Currently recruiting patients at select locations in the US
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.